1 October 2021 - Pfizer today announced that the Japanese Ministry of Health, Labour and Welfare has approved Cibinqo (abrocitinib), an oral, once daily, Janus kinase 1 inhibitor, for the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and older with inadequate response to existing therapies. 

Cibinqo will be available in Japan in doses of 100 mg and 200 mg.

The approval of Cibinqo in Japan was based on the results from 1,513 patients across four Phase 3 trials, ranging from 12 to 16 weeks of treatment, and a long-term extension study from a robust clinical trial program.

Read Pfizer press release